Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
6-16-2016 12:00 AM

The Development Of Novel Imaging Modalities & High-throughput
Drug Screening Platforms In The Drosophila Melanogaster Model
of Human Calcium Oxalate Nephrolithiasis
Sohrab Naushad Ali, The University of Western Ontario
Supervisor: Dr. Hassan Razvi, The University of Western Ontario
Joint Supervisor: Dr. Hon Sing Leong, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Surgery
© Sohrab Naushad Ali 2016

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Disease Modeling Commons

Recommended Citation
Ali, Sohrab Naushad, "The Development Of Novel Imaging Modalities & High-throughput Drug Screening
Platforms In The Drosophila Melanogaster Model of Human Calcium Oxalate Nephrolithiasis" (2016).
Electronic Thesis and Dissertation Repository. 4106.
https://ir.lib.uwo.ca/etd/4106

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
Nephrolithiasis is a common urological disorder. Despite advances in the surgical treatment
of kidney stone disease, research into its prevention and medical management remain
stagnant. This is due to lack of viable pre-clinical models to study the disorder. In this
project, we develop and characterize a robust Drosophila melanogaster model for human
calcium oxalate nephrolithiasis. Using this model, we have developed intravital imaging
techniques to study stone formation and novel high-throughput drug screening platforms. We
successfully demonstrate calcium oxalate stone formation by sodium oxalate and ethylene
glycol supplementation, with subsequent intravital imaging using bisphosphonate based
fluorescent probes. Screening of 360 experimental compounds has revealed 6 compounds
that inhibit calcium oxalate stone formation. We intend to further investigate the mechanism
of action of these compounds, use them as a starting point for rational drug design and to
develop Drosophila melanogaster models for other kidney stone types.

Keywords
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melanogaster, drug screen, fluorescent probes, GAL4/UAS system, insect model, intravital
imaging, kidney stone disease, malpighian tubule, nephrolithiasis, notdronate.
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Chapter 1

1

Introduction

Nephrolithiasis is a common urological disorder with an estimated prevalence of 8.4% in
North America1. Studies such as the one conducted by the National Health and Nutrition
Examination Survey (NHANES) reveal that the prevalence is steadily rising, from a
modest 3.8% reported in 1976 to 8.4% in 20102. It is estimated that 19% of men and 9%
of women will develop a symptomatic stone during their lifetime1. Although mortality
rates due to stone disease are low, the morbidity is significant and is exacerbated by stone
recurrence, with rates as high as 50% in the first five years and 80% throughout life3.
Kidney stone disease also continues to be a significant healthcare burden. The total
spending on nephrolithiasis related healthcare is estimated at a staggering US$ 5.3 billion
annually, with 3.1 million work days lost, that account for an additional indirect cost of
US$ 775 million annually4,5.

1.1 Kidney Stone Subtypes
The vast majority of kidney stones are calcium based and account for 75% of all stones
formed6. Of these, 80% are calcium oxalate and the rest are calcium phosphate7.
Although some stones are pure, most are heterogeneous in composition, which reflect the
complex pathophysiological pathways that govern stone formation. Most calcium oxalate
stones also contain small quantities of hydroxyapatite and uric acid6,8. Uric acid stones
are the second most common, accounting for 8-14% of stones formed. 5% of these are
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pure uric acid and others contain small amounts of hydroxyapatite and struvite6. The third
most common is the bacterial infection associated struvite (magnesium ammonium
phosphate) stone at 2-6%9. The purely genetic cystine stone accounts for the remainder 23%10. Xanthine, an additional genetic stone subtype, is extremely rare and makes up only
0.1% of total stone burden11. Occasionally, high doses of drugs such as triamterene,
sulphonamides and indinavir can precipitate and form crystals in the urinary tract12.
The distribution of various stone types in a typical North American population are
illustrated in Figure 1.

8%

3%

Calcium Based Stones

14%

Uric Acid
Struvite
Cys=ne
75%

Figure 1: Distribution of stone subtypes in a North American population.

1.2 Pathogenesis of Kidney Stone Disease
The pathogenesis of kidney stone disease is complex and often poorly understood. It
encompasses a wide variety of genetic and metabolic imbalances such as hypercalciuria
and hyperoxaluria plus environmental factors such as the diet that collectively regulate
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urine composition13. Generally, the underlying defect in all stone types is the
dysregulation of urinary composition and pH that allows for the super saturation and
precipitation of its constituents6. Other common risk factors include urinary stasis due to
obstruction, low fluid intake that results in a concentrated urine and dietary trends such as
an increased consumption of salt and protein6,7,9. Subtle factors such as climate,
temperature changes and geographic location have also been implicated in the rising
prevalence of kidney stone disease14,15.

1.2.1

Calcium Oxalate

Calcium oxalate nephrolithiasis is a complex genetic disorder that is characterized by
multiple metabolic abnormalities and environmental factors such as the diet16,17.
Hypercalciuria (a urinary calcium excretion of > 6.24 mmol/day in women and > 7.49
mmol/day in men) is the most common metabolic abnormality identified in 30-60% of
calcium stone formers18,19. Two thirds of these patients present with ‘idiopathic’
hypercalciuria and have no identifiable cause. Idiopathic hypercalciuria can either be due
to increased intestinal absorption (absorptive), increased bone turnover (resorptive) or
increased renal losses (renal hypercalciuria), with most patients exhibiting more than one
abnormality. The pathophysiology of absorptive hypercalciuria is varied, with some
patients exhibiting signs of vitamin D dependent hypercalciuria characterized by
increased circulating levels of activated vitamin D, that causes increased intestinal
absorption of calcium and increased bone resorption through osteoclast activation20–22. A
subgroup of hypercalciuric patients have vitamin D independent hypercalciuria, which is
most likely due to an up regulation of the vitamin D receptor (VDR), as shown in a
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variety of animal studies23,24. Renal leak hypercalciuria is less common and caused by
defective tubular reabsorption of filtered calcium which leads to increased parathyroid
hormone release, increased activated vitamin D and increased intestinal calcium
absorption25. Chronic acidemia, such as that which occurs in renal tubular acidosis, also
increases the risk of calcium oxalate stone formation by causing hypercalciuria,
hypocitriuria and an acidic urine26. The most common form of resorptive hypercalciuria
is primary hyperparathyroidism, which leads to increased levels of parathyroid hormone
causing increased bone turnover and increased intestinal calcium absorption16,27.
Hypophosphatemia has also been implicated in the development of hypercalciuria by
stimulating the activation of vitamin D28. Mutations in the sodium-hydrogen exchange
regulator factor 1 (NHERF1) have been identified in several patients as a possible cause
for renal phosphate leak leading to hypophosphatemia29,30.
Hyperoxaluria (a urinary oxalate excretion of > 0.5 mmol/day) is detected in 10-50%
patients and is an independent risk factor in calcium oxalate stone formation31.
Endogenous oxalate overproduction occurs in inborn errors of metabolism such as
primary hyperoxaluria or metabolic breakdown of excess dietary vitamin C32–35.
Increased intestinal absorption of oxalate occurs in low calcium diets or due to increased
intestinal calcium absorption, such as in hypercalciuric patients or small bowel disorders
like Crohn’s disease, surgical bowel resection and other malabsorption syndromes36–38.
Normally, calcium in the gut forms complexes with oxalate to increase enteric clearance.
A reduction of calcium in the gut leads to the increased absorption of oxalate and
concomitant oxaluria39,40. Recently, the alteration of the gut microbiota with the loss of
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Oxalobacter formigenes, an oxalate degrading bacteria, has also been implicated in
increasing the risk of calcium oxalate stone formation41–44.
Hyperuricosuria is also commonly detected in patients with calcium oxalate stones45.
However, the link between high levels of uric acid and calcium stone formation has not
yet been established19. Previous theories for uric acid crystals serving as a nidus for
calcium oxalate deposition have since been refuted6.
Other mechanisms by which calcium oxalate stones form are reductions in the levels of
urinary crystallization inhibitors such as citrate and the endogenously produced tammhorsfall protein (uromodulin), nephrocalcin and uropontin46,47. Citrate acts by forming
soluble complexes with calcium to increase renal clearance and prevent binding to
oxalate48. Citrate also inhibits crystal aggregation, an important step in stone formation49.
Hypocitriuria (a urinary citrate of < 1.67 mmol/day) is associated with an increased risk
of calcium stone formation and can occur in isolation or with other metabolic
abnormalities. Hypocitriuria is common in acidemic states such as chronic diarrhea, renal
tubular acidosis and certain drugs. Diets high in protein also result in lower levels of
urinary citrate50,51.
Diet also plays an important role in the formation of calcium oxalate stones by regulating
the urinary composition. Low fluid intake leads to concentration of the urine and super
saturation of calcium and oxalate. By far, the most effective intervention for reducing the
risk of stones is increasing fluid intake52. Alcohol and sugar sweetened drinks are
associated with increased risk of stone formation, while orange and lemon juice that are
rich in citrate, plus tea and coffee reduce the risk of stone formation53–56. Diets high in
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sodium and animal protein increase the risk of stone formation50,57. Diets high in
potassium and phytates seem to lower risk58,59.

1.2.2

Uric Acid

Uric acid, which is a byproduct of normal purine metabolism, has two dissociable protons
and generally exists as hydrogen urate that forms soluble salts with sodium, potassium
and ammonium60. The two main pathological features that predispose a patient to uric
acid stone formation are an acidic urinary pH and increased amounts of uric acid in the
urine. Alterations in the urinary pH and a high concentration of uric acid drive the
conversion of soluble hydrogen urate into the relatively less soluble uric acid.
H ! + Urate → Uric Acid
The effects of urinary pH on uric acid solubility are dramatic, with the solubility of
dropping to 0.09 mmol/l at a pH of 5 compared to 1.2 mmol/l at a pH of 760–62. The
association between urinary pH and uric acid crystal precipitation explains the high
prevalence of uric acid stones in patients that have a low fluid intake, chronic diarrhea or
small bowel disease that cause a loss of bicarbonate and a concentrated acidic urine13,36.
Uric acid stones are also more prevalent in populations that live in hot arid climates63.
Recently, type 2 diabetes and metabolic syndrome have also been implicated in the
increased risk of forming uric acid stones by reducing ammoniagenesis and reducing
urinary pH64,65. Diets rich in red meat can increase the risk of forming uric acid stones by
providing excesses of methionine which is metabolized to sulfuric acid, which in turn
decreases the urinary pH50.
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Hyperuricosuria can also contribute to uric acid stone formation with extremely high
urinary levels causing crystallization of uric acid regardless of the urinary pH66. This is
common in patients with gout, myeloproliferative disorders, tumor lysis syndrome and
other genetic enzyme defects such as glucose-6-phosphatase deficiency67,68.

1.2.3

Struvite

Struvite is a hard mineral complex composed of magnesium ammonium phosphate69. It
generally forms in alkaline conditions that cause a decrease in the solubility of phosphate
which then forms complexes with other urinary constituents such as magnesium and
ammonium. The underlying pathology of struvite stones are infection with urea splitting
bacteria such as Klebsiella, Proteus, Pseudomonas and Staphylococcus70,71. These
bacteria produce Urease which split urea into ammonia and carbon dioxide.
Urea → 2NH! + CO!
The ammonia combines with water to produce ammonium and a hydroxyl ion which
increases urinary pH.
NH! + H! O → NH! + OH !
Struvite stones often grow very rapidly forming staghorn stones that cause the complete
occlusion of the renal collecting system. Females and patients at higher risk of urinary
tract infection commonly form struvite stones72,73.
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1.2.4

Cystine

Cystine, which is a homo-dimer of the amino acid cysteine, is a rare cause of kidney
stone disease in humans. It is caused by the impaired proximal tubular reabsorption of
filtered cystine due to mutations in the dibasic amino acid transporters SLC3A1 and
SLC7A910. The cystine transporter belongs to a family of heteromeric amino acid
transporters, with the SLC3A1 gene coding for the heavy rBAT unit and the SLC7A9
coding for the light b0,+AT unit74. Both genes are required for proper localization and
transit of the transporter to the cell apical membrane. The defective transporters cause
abnormalities in renal and intestinal cystine absorption leading to high concentrations of
cystine in the urine with super saturation and crystallization75,76. Patients with cystine
nephrolithiasis usually present at an early age and have a protracted disease history77.

1.2.5

Miscellaneous

Xanthine nephrolithiasis, an extremely rare form of kidney stone disease, is caused by
mutations of the enzyme Xanthine dehydrogenase that catalyzes the conversion of
hypoxanthine to xanthine and xanthine to uric acid11,78. This leads to xanthinuria with
super saturation and precipitation of xanthine crystals.
Routinely prescribed medications can, on occasion, cause crystal deposition and
nephropathy. Drugs such as sulfadiazine for toxoplasmosis, acyclovir for herpes zoster
and indinavir, a protease inhibitor for HIV infection, reach high concentrations in the
renal tubules and due to their relative insolubility precipitate and form small stones79.
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1.3 Presentation of Kidney Stone Disease
Pain is the most common symptom associated with kidney stone disease, although a
subset of patients have clinically asymptomatic nephrolithiasis and are diagnosed
inadvertently during radiologic imaging of the abdomen for unrelated causes. Patients
with asymptomatic nephrolithiasis that have not experienced an episode of renal colic in
the past, are less likely of becoming symptomatic in the future80. However, the inverse is
true in patients with a previous history of kidney stones that are diagnosed with
asymptomatic nephrolithiasis.
The pain associated with kidney stones is usually colicky in nature and may wax and
wane or present acutely as an unrelenting severe flank pain. Unilateral flank pain and
costo-vertebral angle tenderness are common in stones that cause obstruction in the renal
pelvis or upper ureter. Stones that cause obstruction in the lower ureter cause pain that
radiates to the groin, testicle or labium. Patients with acute ureteric obstruction usually
present with excruciating pain, accompanied by nausea and vomiting. Persistent vomiting
can lead to metabolic alkalosis and electrolyte abnormalities.

Both gross and microscopic hematuria occur in approximately 70% of patients with
nephrolithiasis, however, the absence of hematuria in a patient with flank pain does not
rule out kidney stone disease81–84. The time of onset of acute pain seems to correlate
positively with the presence of hematuria, with hematuria being present in 95% of
patients at day one and in only 68% at day three82.
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Besides pain and hematuria, patients can present with passage of fine gravel or small
stones. Persistent obstruction of the urinary tract can lead to kidney dysfunction and
permanent damage. Occasionally, patients may also present with fever due to
superimposed urinary tract infections caused by urinary stasis and obstruction. Kidney
stones are known to harbor virulent bacteria and are thus a nidus for infection85.

1.4 Current Animal Models for Human Nephrolithiasis
Despite being a significant healthcare burden and a risk factor for chronic renal disease,
research into and our understanding of the mechanisms that govern stone formation
remain limited. This is mostly due to the lack of suitable pre-clinical models that
recapitulate the pathophysiology of the disorder. An ideal kidney stone disease model
should be simple, highly reliable and consistent in stone formation, whilst maintaining
fidelity to the elemental composition of human stones. Additionally, these models must
also be amenable to non-invasive imaging and permit the investigator to antagonize stone
formation in order to assess the value of potential therapeutic agents.
Historically, rats have been the animal of choice for studying nephrolithiasis, however,
canine and porcine models also exist86–89. Although the kidneys of these animals have
been used in the past for understanding renal structure and physiology, there are
fundamental anatomical differences that make them poor candidates as models for kidney
stone disease. Their kidneys are generally smaller in size, unipapillate compared to the
multipapillate human kidneys and have fewer nephrons and tubules which make them
incapable of forming large kidney stones90. Additionally, spontaneous nephrolithiasis in

11

rats is extremely rare and there are currently no reports of spontaneous stone formation in
the urinary tracts of these animals91.
Stone formation in the rat model of nephrolithiasis is induced by the administration of
lithogenic agents such as sodium oxalate, ammonium oxalate, hydroxy-L-proline,
ethylene glycol and glycolic acid, all of which produce hyperoxaluria88,92–95. Most of the
lithogenic agents are administered either by supplementation in the diet or through
intraperitoneal injections, which can prove cumbersome86,93,94,96. Additionally, the
administration of these lithogenic agents does not accurately recreate the metabolic
milieu required for stone formation and are often nephrotoxic leading to renal failure and
death91,97. The size, amount and duration of calcium oxalate crystal excretion is directly
related to the duration of lithogenic administration, with crystal formation ceasing after
the lithogenic agent is withdrawn98. Most of the calcium oxalate crystals form in the
tubular lumina and are non-adherent to the renal epithelium, subsequently being washed
out in the urine98.
Rat models of nephrolithiasis are also highly unreliable, with stone formation following
unpredictable and protracted time lines. Low dose concentrations of 1% w/v ethylene
glycol produced calcium oxalate nephrolithiasis in only 3 of 13 male Sprague-Dawley
rats and 0 of 12 females at 4 weeks99. Combinations of lithogenic agents produced similar
results. Rats administered a combined treatment of 0.75% w/v ethylene glycol and 2%
w/v ammonium oxalate produced crystalluria at 3 days and nephrolithiasis at 7 days.
These stones were generally < 200 µm in size and only found in the bladder aspirate100–
102

. Similar results were obtained in more recent studies using ethylene glycol and

glyoxylate administration. Minimal crystal deposition was seen at 1 and 2 weeks in rats
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fed a 1% w/v ethylene glycol diet, with intraperitoneal injections of glyoxylate slightly
improving results94.
In addition to the above drawbacks, the only method to accurately verify and monitor
stone deposition, is to sacrifice the animals. This causes an unnecessary loss of animals
and increased costs. Similarly, the use of this model does not allow the investigator to
visualize stone burden in vivo, limiting their ability to identify therapeutic targets or
evaluate the efficacy of a potential therapy. The infrastructure requirements and costs
associated with rat based studies make large scale studies unfeasible. Small sample sizes
used in most studies lead to questionable results at best. Also, the processing of the
kidney tissue does not allow for the collection of stone material, which leads to
difficulties in verifying stone composition.
Currently, the majority of rat models aim to elucidate the mechanisms involved in
calcium oxalate stone formation. Although rat models exist for other stone types, such as
cystine, these models suffer the same setbacks described above103. Further work is needed
to refine the current animal models for human nephrolithiasis.
In light of the above limitations and the cost prohibitive nature of working with current
animal models, the urological community has been prompted to develop newer, more
novel models for human nephrolithiasis.
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1.5 The Drosophila melanogaster Model of Human
Nephrolithiasis
Drosophila melanogaster (DM) has recently emerged as a viable model for human
nephrolithiasis104. Although it might seem like an unlikely candidate at first, it shares a
lot in common with humans and has many advantages over current animal models.

1.5.1

Advantages of Drosophila melanogaster

Drosophila is a versatile model organism that has been studied for over a 100 years, with
novel research carried out in the field of genetics, including translational research in
human disorders105. It is a proven translational and drug discovery model for numerous
conditions such as Alzheimer’s disease and diabetes106. Furthermore, discoveries using
Drosophila have improved our understanding of a variety of human renal diseases. For
example, research in Drosophila identified the gene vha55 that encodes for the B subunit
of the V-ATPase pump, mutations of which lead to renal acidification and death107,108.
This work preceded the discovery of sub-lethal mutations in human V-ATPase pumps as
a cause for renal tubular acidosis109. Xanthinuria, a rare cause of nephrolithiasis, which is
due to mutations in the enzyme Xanthine dehydrogenase (XHD), was unknown until the
cloning of homologs in Rosy and Maroon-like Drosophila, leading to the discovery of
mutations in the human molybdenum cofactor sulfurase gene78. Similarly, other genes
such as dPrestin, which encodes for the transmembrane oxalate transporter SLC26A5 in
Drosophila, have been implicated in the formation of calcium oxalate stones110.
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The Drosophila genome (180 million base pairs) is fully sequenced and highly conserved
with humans. Despite millennia of divergent evolution, over 70% of DM genes have
human homologs111. These homologs and other gene orthologs for human disorders can
easily be identified using online tools such as the DIOPT-DIST database112. An
exhaustive online database for all fly genes and microarray expression data are freely
available to the research community113,114. Additionally, the fly genome is easily
modifiable using established genetic tools such as the GAL4/UAS system115. This bipartite system allows for simple mating based schemes that can spatio-temporally control
the expression of the Drosophila genome. Through systematic mutagenesis and Pelement insertion, hundreds of fly lines have been produced that contain upstream
activation sequences (UAS) and the yeast transcription activator factor (GAL4)116. Two
fly lines, one containing the UAS construct followed by the gene of interest and another
expressing GAL4 in a tissue specific pattern, are mated to produce progeny that possess
both. GAL4 binds to the UAS activating the downstream sequence resulting in either
gene expression or knockdown through small hairpin RNA interference.
Drosophila has a short life cycle of 14 days and an adult life span of approximately 40-50
days, which allows for multiple experiments to be carried out in a short period of time.
Various strains of DM are freely available and can be mail ordered within days, usually at
minimal cost (~$20 CAD), through the international stocking centers at Bloomington,
Indiana, USA, the National Institute of Genetics, Mishima, Japan or the Kyoto Stock
Centre, Kyoto, Japan. The Drosophila research community is vibrant, with most
researchers publically sharing their proprietary fly lines. These fly stocks can be
maintained with minimal reagents and at minimal cost (<$20 CAD per year) which
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makes their long term use feasible. Fly husbandry is an easy skill that can be learned with
very little training and does not require an investment in expensive infrastructure.
Finally, current ethics guidelines exempt the use of invertebrates such as DM, which
removes the ethical constraints associated with research in current animal models of
human nephrolithiasis.

1.5.2

Drosophila Renal Anatomy

The DM renal system is composed of two components, the nephrocytes and the
malpighian tubules. The nephrocytes are a distinct group of cells concentrated near the
esophagus and heart. They filter the insect hemolymph, which bathe the internal organs,
similar to the human glomerulus. These specialized cells are high adapted and are
analogous to the podocytes in the human glomerulus (Figure 2). The filtration function
of human podocytes is highly dependent on the slit diaphragm component proteins such
as nephrin and NEPH1. Orthologs of both these genes are high expressed in Drosophila,
loss of which, results in a filtration syndrome similar to congenital nephrotic syndrome of
the Finnish type117.
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Figure 2: Schematic diagram comparing vertebrate podocytes to insect nephrocytes. (A)
Podocyte glomerular filtration barrier with basement membrane (bm), slit diaphragm (sd)
and foot processes (fp). Ultrafiltration direction is show with red arrows. (B) Insect
nephrocytes with slit membranes similar to podocytes. Adapted with permission from
Weavers H. et. al 2010.

DM have 4 malpighian tubules, which are divided into anterior and posterior pairs. These
tubules dangle freely in the insect hemolymph and coalesce into a common ureter before
draining into the gut at the junction between the mid and the hind gut (Figure 3). Each
tubule is approximately 2 mm long and has a 17 µm wide lumen118. The malpighian
tubules are further divided into distinct segments. The initial segments are generally
wider and serve as a storage organ for naturally formed concretions of calcium phosphate
and glycosaminoglycans119. These concretions are thought to be involved in fly calcium
homeostasis similar to the human skeleton. A short transitional segment is followed by a
long main segment which is made up of principal cells with interspersed stellate cells that
collectively take part in ion and solute transport analogous to the human nephron (Figure
4).
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Figure 3: The Drosophila melanogaster excretory tract consists of 2 pairs of malpighian
tubules, 1 anterior and 1 posterior, and are connected to the gut via a common ureter.
Adapted with permission from Miller J. et. al 2013.

Figure 4: Similarities between the human renal nephron and Drosophila malpighian
tubules. Adapted with permission from Weavers H. et. al 2010.
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The main segment is mainly responsible for urine production, with the principal cells
possessing ion and solute transporters similar to the cells in the proximal convoluted
tubules and the collecting ducts in human kidneys (Figure 5). The principal cells contain
basolateral membrane transporters for Na+, K+ and Cl- plus an Na+ dependent bicarbonate
exchanger. Ion gradients are maintained using an H+ATPase pump which drives the
secondary transport of Na+ and K+. The stellate cells mostly regulate H2O and Clbalance. Besides having a lot in common with the human nephron, Drosophila
malpighian tubules are easily dissected and visualized using simple techniques such
bright field and polarized light microscopy.

Figure 5: Schematic diagram depicting Drosophila principal and stellate cells, with their
respective ion and solute co-transporters. Adapted with permission from Miller J. et. al
2013.
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Additional parameters, that may be useful in elucidating the basic mechanisms governing
stone formation, such as ion electrophysiology, urine composition and pH can easily be
measured in the malpighian tubules using simple techniques such as the Ramsay
assay118,120.

1.5.3

Current Drosophila Nephrolithiasis Research

Since the emergence of Drosophila as a novel model for human kidney stone disease, a
substantial body of literature has accumulated, utilizing the model in unique ways. Chen
et. al first described calcium oxalate nephrolithiasis by feeding the flies diets containing
the lithogenic agent’s ethylene glycol, hydroxy-L-proline and sodium oxalate121. They
showed dose dependent calcium oxalate crystal deposition in the malpighian tubules after
feeding with the lithogenic diets. Potassium citrate, which complexes excess calcium,
reduced crystal deposition in the malpighian tubules. Similarly, Hirata et. al describe a
genetic model for calcium oxalate nephrolithiasis through selective knockdown of the
oxalate co-transporter SLC26A5 (dPrestin)110. Selective knockdown of the dPrestin gene
using the GAL4/UAS system reduced calcium oxalate stone formation in flies fed a
sodium oxalate diet, outlining the importance of oxalate metabolism and transport in
calcium oxalate stone formation. Melamine, a lithogenic agent notorious for having
caused kidney stone epidemics in dogs fed food accidentally laced with it, has also been
used to form calcium oxalate stones in Drosophila122. Recent work by Chi et. al, has
successfully produced xanthine nephrolithiasis in Drosophila by selective knockdown of
the enzyme Xanthine dehydrogenase (XDH) and identified the role of zinc in the
formation of Randall plaques123. Lang et. al recently described a uric acid model of
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nephrolithiasis by selective knockdown of the Uricase enzyme in the malpighian
tubules124. In Drosophila, purine metabolism leads to the formation of urate which is then
converted to allantoin via the Uricase enzyme. GAL4/ UAS mediated knockdown of
Uricase resulted in the accumulation of uric acid concretions in the malpighian tubules.
This was mitigated with the use of drugs such as allopurinol. Other groups have been
investigating the effects of commercially available drinks such as citrate containing juices
and soft drinks in the Drosophila model of calcium oxalate nephrolithiasis125,126.
Traditional Chinese medicinal plants have also been tested using the Drosophila
model127. Potential drugs have also been tested. Landry et. al demonstrate reduced
calcium oxalate stone deposition in the malpighian tubules with the administration of
sulfate and thiosulfate, highlighting the importance of these compounds as competitive
inhibitors of calcium oxalate crystalization128.

1.6 Objectives & Research Aims
Objective 1: To develop a robust and reliable Drosophila melanogaster model for
calcium oxalate nephrolithiasis.
Research Aim: Previous studies with the administration of lithogenic agents have
reported varying results in regards to calcium oxalate stone deposition. Our goal is to
identify the optimal lithogenic agent and its concentration, so as to reliably produce
calcium oxalate stones in Drosophila malpighian tubules. We will use the lithogenic
agent’s ethylene glycol and sodium oxalate at concentrations of 0.05%, 0.1%, 0.5% and
1% w/v ratio, and measure stone burden using a combination of polarized light and
fluorescent microscopy.
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Objective 2: To develop ex vivo imaging capabilities using novel bisphosphonate
based fluorescent probes.
Research Aim: Adequate visualization and quantification of stone burden remains a
limiting factor in both animal and Drosophila models of human nephrolithiasis. Our
laboratory has developed novel bisphosphonate based fluorescent probes that have
previously been shown to bind calcium oxalate129. Use of these probes will allow us to
visualize and quantify stone burden, plus serve as a starting point for optimizing in vivo
imaging protocols.
Objective 3: Perform survival studies to characterize the effect of lithogenic diets on
Drosophila life span.
Research Aim: Lithogenic agents cause calcium oxalate stone deposition by inducing a
state of hyperoxaluria. At higher concentrations, these agents can be toxic. For our model
to be useful we aim to characterize the effects of lithogenic agents on the life span of
Drosophila. We will achieve this by performing survival studies on Drosophila fed
varying concentrations of lithogenic diet. This will allow us to select the optimal
concentration of lithogenic agent for our subsequent experiments.
Objective 4: To characterize Drosophila stone composition and morphology.
Research Aims: In order to accurately model human calcium oxalate nephrolithiasis,
Drosophila stones must be similar in composition and morphology to human stones. We
aim to isolate stone material from the malpighian tubules and characterize stone
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composition/morphology using a combination of scanning electron microscopy and
energy dispersive x-ray spectroscopy.
Objective 5: To develop novel intravital imaging techniques for studying stone
formation in vivo.
Research Aims: A fundamental drawback in animal models of nephrolithiasis is the
inability to visualize or quantify stone burden in vivo. Although the use of Drosophila
simplifies this due to the ease of malpighian tubule dissection, developing intravital
imaging techniques would be useful in tracking stone formation and quantifying the
effect of potential interventions. We will develop a transgenic fly line that express red
fluorescent protein in their malpighian tubules. Utilizing multi-channel resonance laser
confocal microscopy, we will optimize and develop imaging protocols for visualizing the
malpighian tubules in vivo. This will provide a sound platform for subsequent imaging
protocols.
Objective 6: To develop a high-throughput noninvasive drug screening platform in
the Drosophila model of human nephrolithiasis.
Research Aim: Current animal models do not allow for large scale high-throughput
screening of potential therapies. We will screen an experimental drug library of 360
compounds that have been previously used as a basis for rational drug design130. Using
our Drosophila model we will develop and validate a high-throughput noninvasive
screening method by quantifying stone burden indirectly in the fly fecal matter. In the
process we hope to identify compounds that antagonize calcium oxalate stone formation.
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Chapter 2

2

Materials and Methods

This study did not require prior approval by the University of Western Ontario’s animal
use subcommittee, as the experimental use of Drosophila melanogaster is exempt from
current ethics guidelines.

All Drosophila melanogaster stocks were obtained from the Bloomington Stock Center,
Indiana, United States (http://flystocks.bio.indiana.edu), the Kyoto Stock Center, Kyoto,
Japan (https://kyotofly.kit.jp/cgi-bin/stocks/index.cgi) and the National Institute of
Genetics, Mishima, Japan (http://www.shigen.nig.ac.jp/fly/nigfly/).

2.1 Drosophila melanogaster Rearing
All Drosophila melanogaster stocks were reared in a dedicated Drosophila incubator
(DT2-MP-47L Tritech Research Inc., Los Angeles, United States) at 22°C, 40% ambient
humidity and a 12-12 hour light-dark cycle. Drosophila melanogaster stocks utilized in
GAL4/UAS system experiments were reared at 29°C, 40% ambient humidity and a 12-12
hour light-dark cycle. All stocks were regularly inspected for signs of bacterial, fungal
and mite infestations. Stocks were rotated to fresh food media every 4-5 days to prevent
contamination, reduce competition between adult flies and larvae for food media, and to
ensure an adequate supply of adult flies for experiments.
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2.2 Preparation of Food Media
Drosophila food media was prepared manually in 1 liter batches on a bi-weekly schedule
to avoid contamination and to ensure optimal freshness. After the media ingredients were
weighed using a digital scale (Sartorius AG, Göettingen, Germany), they were mixed in
distilled water and heated using a standard laboratory hot plate (Salton Appliances Corp.,
Dollard Des Ormeaux, Canada). The prepared media was then manually dispensed into
wide polypropylene vials (32-114 Diamed Inc., Mississauga, Canada). The vials were
allowed to rest for 8-12 hours to allow for adequate media solidification. It was noted that
allowing the vials to rest for this period reduced moisture ‘bleed’ upon subsequent use of
the food media. After resting, the vials were closed using dense cellulose acetate plugs
(49-101 Diamed Inc., Mississauga, Canada) and labelled accordingly. All prepared food
media was stored in a 4°C humidity controlled cold room until further use. Food media
was stored for a period of 1 month after which unused media was discarded.

2.2.1

Standard Food Media

The standard Bloomington stock center recipe was used for the preparation of standard
Drosophila food media. The ingredients required for the preparation of 1L of food
medium are listed in Table 1.
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Ingredient

Amount

1

Distilled Water

1000 ml

2

Drosophila Agar (66-103 Diamed Inc.)

5.7 g

3

Inactive Yeast (62-106 Diamed Inc.)

19.3 g

4

Soy Flour (62-115 Diamed Inc.)

10 g

5

Yellow Corn Meal (62-100 Diamed Inc.)

73 g

6

Light Corn Syrup (62-117 Diamed Inc.)

75 ml

Acid Mix
7

¼ parts Propionic Acid (1368 Sigma Inc.)
5 ml
¾ parts Phosphoric Acid (290017 Sigma Inc.)
Optional:

8

5 ml
Tegosept 30% Solution (20-258 Diamed Inc.)
Total

1000 ml

Table 1: List of ingredients required for the preparation of standard Drosophila food
media.

700 ml of distilled water was brought to a boil and agar added until it was well dissolved.
Adequate cooking of the agar allowed for better solidification and adherence of the food
media to the vial walls. This step was followed by the addition of yeast, soy flour and
corn meal, and the solution allowed to simmer at medium heat for 10 minutes. 75 ml of
corn syrup was mixed with the remaining 300 ml of distilled water and added to the
solution and allowed to simmer for 5 minutes. 5 ml of acid mix was then added and the
final solution left to cool to 60°C, after which it was ready to be dispensed into
Drosophila vials. The acid mix of propionic acid and phosphoric acid work to inhibit
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bacterial and fungal growth. Occasionally, the acid mix was substituted with 5ml of 30%
Tegosept® solution for weaker strains prone to fungal overgrowth.

2.2.2

Lithogenic Food Media

The lithogenic agent’s sodium oxalate (71800 Sigma Inc.) and ethylene glycol (324558
Sigma Inc.) were used to induce calcium oxalate stone formation in wild type Canton-S
flies (Bloomington Stock # 1). Lithogenic diets containing these agents were prepared at
concentrations of 0.05%, 0.1%, 0.5% and 1% w/v. The agents were thoroughly dissolved
in water before the preparation of the food media using the recipe above.

2.3 Drosophila Lifespan Studies
In order to identify the optimal concentration of lithogenic agents for use in our
subsequent experiments, lifespan studies were carried out to determine the relationship
between lithogenic agent concentration, Drosophila lifespan and calcium oxalate stone
burden. The standard protocol for Drosophila melanogaster life span measurement was
used for this experiment131.

2.3.1

Age Matching

To ensure all adult flies used for lifespan studies were of the same age and health, wild
type Canton-S (Bloomington stock #1) were age matched. 100-150 adult wild type
Canton-S were isolated in large egg collection cages (59-101 Diamed Inc.) over grapejuice agar plates (Figure 6). A 1 cm wide dollop of active yeast paste (62-103 Diamed
Inc.) was placed in the center of the grape-juice agar plates. Grape-juice agar stimulated
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mating and provided a solid surface for the deposition of eggs. The dark red color of the
agar contrasted well with the white eggs, allowing for better visualization and collection.
The active yeast provided nutrition to the adult flies inside the egg collection cages. Eggs
were allowed to collect on the surface of the agar plates for a day, after which they were
replaced with a fresh plate and the old one discarded. This ensured that all subsequent
eggs laid would be of approximately the same age. On the second day, the egg collection
cages were opened and the adult flies discarded in an alcohol filled fly morgue. A cell
scrapper was used to remove the central yeast, taking care not to damage or remove the
deposited eggs. The surface of the grape juice agar plate was washed with 5 ml of PBS
(Wisent Inc., St. Bruno, Canada) and a soft cotton bud was used to dislodge the deposited
eggs. This egg/PBS suspension was then funneled into a 15 ml collection tube. The eggs
were allowed to settle via gravity for 5 minutes and the supernatant removed from the
tube. The settled egg ‘pellet’ was then washed with PBS at least twice or until the
supernatant was clear. 100 µl of PBS was added to the washed eggs. 32 µl aliquots of this
egg/PBS suspension was added to fresh room temperature standard media. Newly
eclosed, age matched adult flies were collected after 10 days for use in lifespan
experiments.
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Figure 6: Grape-juice agar plates and egg collection cages used for age matching of
Drosophila melanogaster.

2.3.1.1

Preparation of Grape-Juice Agar Plates

500 ml batches of grape-juice agar were prepared as required. The ingredients required
for the preparation of grape-juice agar plates are listed in Table 2. Agar and sucrose was
added to distilled water and heated until both were adequately dissolved. Grape-juice
concentrate was then added and rigorously stirred. The solution was allowed to cool to
65°C, followed by the addition of ethanol and glacial acetic acid. Ethanol and glacial
acetic acid inhibit bacterial and fungal growth. The solution was then poured into 100
mm plastic petri dishes (VWR Inc., Radnor, United States) and allowed to solidify at
room temperature. The plates were subsequently labelled and stored in a 4°C cold room
until further use.
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Ingredient

Amount

1

Distilled Water

375 ml

2

Bacteriological Agar (5306 Sigma Inc.)

12 g

3

Sucrose (7903 Sigma Inc.)

22 g

4

Grape Juice (Welch’s grape-juice concentrate)

110 ml

5

Ethanol (Sigma Inc.)

10 ml

6

Glacial Acetic Acid (2183 Sigma Inc.)

5 ml

Total

500 ml

Table 2: List of ingredients required for the preparation of grape-juice agar plates.

2.3.2

Lifespan Studies

30 age matched wild type Canton-S flies were anesthetized using CO2 narcotization
(Flystuff Inc., San Diego, United States) and added to lithogenic food media containing
sodium oxalate (71800 Sigma Inc.). 4 test vials were used for each concentration (0.05 %,
0.1 %, 0.5% and 1 % w/v) of sodium oxalate. Wild type Canton-S flies in standard media
were used as the baseline control. The flies were moved to new food media every 2-3
days to avoid competition between adult flies and larvae, which could potentially
adversely affect survival. Deaths were recorded every day and any flies lost during
transfer or adherent to the vial wall during transfer were censored. The recorded data was
saved in a Microsoft excel file. The adult flies were followed till the last death or 40 days,
whichever occurred first.
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2.3.3

Statistical Analysis

The data generated by the life span studies was analyzed using the Statistical Package for
Social Sciences (SPSS, Version 22.0.0.2 Mac, IBM Corp.). Life tables were constructed
and a Kaplan-Meier survival analysis was performed. Statistical significance was tested
using a log-rank test.

2.4 Development of Novel Imaging Modalities in Drosophila
This study aims to develop novel imaging modalities for visualizing and quantifying
calcium oxalate stones in the Drosophila melanogaster model of human calcium oxalate
nephrolithiasis. We have developed novel bisphosphonate based fluorescent probes that
will bind to calcium oxalate calculi and allow us to image these calculi both ex vivo and
in vivo. We have used a combination of polarized light, fluorescent microscopy and
confocal microscopy to study stone formation.

2.4.1

Synthesis of Bisphosphonate Based Fluorescent Probes

All bisphosphonate fluorescent probes were designed and synthesized in collaboration
with the Luyt Laboratory at the Department of Chemistry, Western University, London,
Canada.
Bisphosphonates are well studied group of drugs known to tightly bind to hydroxyapatite
and other calcium containing crystals. Several groups have conjugated the moiety to a
fluorophore and it has previously been used to image the localization of bisphosphonate
groups in bone and in microscopic stone fragments shed in the urine of patients with
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calcium oxalate kidney stones129,132. Our imaging agent consists of the commercially
available bisphosphonate drug Alendronate conjugated to the fluorescent dye fluorescein
isothiocyanate (FITC) (Figure 7). As a negative control, Notdronate was developed by
removal of the bisphosphonate group of Alendronate, leaving 4-amino-1-butanol
conjugated to the dye. All reagents were provided in powder form and stored in an
opaque container at −20°C to avoid photo-bleaching.

Figure 7: Molecular and chemical structure of novel bisphosphonate based fluorescent
probes.
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2.4.1.1

Synthesis of Alendronate-FITC

Sodium alendronate (34.0 mg, 106 µmol) was dissolved in saturated NaHCO3 (aq) (1
ml). Fluorescein (5/6) NHS ester (10 mg, 21 µmol) dissolved in DMF (100 µl) was added
and the solution stirred for 2 days in the dark. The product was dried, suspended in H2O
(1 ml) and dialyzed (cellulose ester, MWCO 0.1-0.5 kD) with water (3 X 500 mL). The
final product’s concentration was determined by the UV absorption (ε493nm = 70,000
M- 1cm-1). The solution was subjected to RP-FCC (Isolera One, Biotage KP-C18-HS
12g cartridge) with a gradient from 0 to 30 % MeOH in H2O. The product was
lyophilized to yield FITC alendronate (8.6 µmol, 41 %) as an orange powder. UP LC-MS
(waters) method: 5-40% acetonitrile in water, both contain 0.1% formic acid, 3mins run;
Calculated m/z 608.07 (MH+), Found m/z: 608.10; RT (min) 1.40. Purity: >95%.

2.4.1.2

Synthesis of Notdronate-FITC

4-Amino-1-butanol (20 mg, 200 µmol) was dissolved in saturated NaHCO3 (aq) (1 ml).
Fluorescein (5/6) NHS ester (10 mg, 21 µmol) dissolved in DMF (100 µl) was added and
the solution stirred for 2 days in the dark. The reaction mixture was subjected to RP- FCC
(0 to 100 % MeOH in H2O) and the final product concentration was determined by the
UV absorption (ε493nm = 70,000 M-1cm-1). The solution was subjected to RP-FCC
(Isolera One, Biotage KP-C18-HS 12g cartridge) with a gradient from 0 to 25 % MeOH
in H2O. The product was lyophilized to yield fluorescein-4-butanol (4.8 µmol, 23 %) as
an orange powder. UP LC-MS (waters) method: 5-40% acetonitrile in water, both contain
0.1% formic acid, 3mins run; Calculated m/z 448.14 (MH+), Found m/z: 448.04; RT
(min) 2.23. Purity: >95%.
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2.4.2

Specificity of Bisphosphonate Based Fluorescent Probes

To assess the specificity of our bisphosphonate based fluorescent probes to
hydroxyapatite and calcium based stones, we subjected synthetic hydroxyapatite particles
(289396 Sigma Inc.) and pulverized samples of infrared spectroscopy confirmed human
calcium oxalate stones to bright field, polarized (TP-2, T-A2, Nikon Inc.) and fluorescent
microscopy (TE-2000, Nikon Inc.) after staining with Alendronate-FITC, NotdronateFITC and PBS as a control. The human stone sample was obtained from the hospital
diagnostic laboratory and would otherwise have been discarded and destroyed. 50 mg of
sample was incubated with 200 µl 0.1 mM Alendronate-FITC, 0.1 mM Notdronate FITC
and PBS in an Eppendorf tube for 15 minutes. The sample was then centrifuged
(Eppendorf Inc., Hamburg, Germany) at 15000 rpm for 5 minutes. The supernatant was
removed and the underlying stone material was washed twice with distilled water in a
similar fashion until the supernatant was clear. This ensured the removal of any unbound
dye. 20 µl of sample suspended in distilled water was mounted on to glass slides with
coverslips and imaged using brightfield, polarized light (TP-2, T-A2, Nikon Inc.) and
fluorescent microscopy (TE-2000, Nikon Inc.).

2.4.3

Diet Induced Calcium Oxalate Stone Formation in
Drosophila

15-20 wild type Canton-S flies were added to wide vials containing either sodium oxalate
media or ethylene glycol media at concentrations of 0.05%, 0.1%, 0.5%, 1% w/v of
lithogenic agent. The flies were fed for a period of 14 days after which they were
removed and processed for staining and imaging.
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2.4.4

Drosophila Dissection Technique

Adult flies were euthanized by CO2 narcotization (Flystuff Inc., San Diego, United
States) prior to dissection. All dissections were carried out under a dissecting microscope
(AmScope Inc., Irvine, United States) in a Sylgard (Dow Corning Inc., Michigan, United
States) lined Pyrex Petri dish (3160100 Sigma Aldrich Inc.). Sylgard lining provided
protection to the delicate Drosophila tissues and also the fine tips of the dissecting
forceps (Fine Science Tools Inc., Vancouver, Canada). Schneider’s Media (0146 Sigma
Aldrich Inc.) was used as a dissection medium because its composition most closely
resembles the insect hemolymph and prevented osmotic cell lysis. A minimal touch
technique was used for dissection. The fly was anchored with fine forceps in the nondominant hand at the superior aspect of the thorax and submerged in the dissecting
media. Using forceps in the dominant hand, the anal region or terminalia, was grasped
below the final abdominal tergites and pulled gently. With gentle pressure the hindgut
emerged first followed by the anterior and posterior tubules. Occasionally, the hindgut
needed to be grasped to facilitate the descent of the malpighian tubules. After emergence
of the malpighian tubules the midgut was severed and the fly discarded. The tubules were
then processed for imaging.

2.4.5

Ex vivo Imaging of Drosophila Malpighian Tubules

Wild type Canton-S flies fed lithogenic diets for 14 days were removed, euthanized with
CO2 narcotization and the malpighian tubules dissected. The tubules were then incubated
in 100 µl of 0.1 mM alendronate-FITC, 100 µl of 0.1 mM notdronate-FITC and PBS
respectively, for 15 minutes. Consequently, the dyes were removed and the tubules
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washed several times with PBS to remove any unbound dye. Fine glass needles were
used to transfer the tubules to poly-l-lysine coated microscope slides (P0425-72EA
Sigma Inc.) for imaging. Brightfield, polarized light and fluorescent microscopy analysis
was performed using an inverted microscope (TE-2000, Nikon Inc.). The steps of this
experiment are demonstrated in schematic form in Figure 8.

Figure 8: Schematic diagram demonstrating the stages in experimental design for ex vivo
staining and imaging of Drosophila melanogaster malpighian tubules.

2.4.5.1

Ex vivo Imaging Analysis

All images were obtained with an inverted light microscope (Nikon Inc., Tokyo, Japan)
using a 10x objective and analyzed using Image J software (NIH http://imagej.nih.gov).
The image background was removed using the process > math > ‘subtract’ feature with a
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value of 25. The images were sharpened with the process > math > ‘unsharp mask’
feature, using a radius of 1 pixel and a mask weight of 0.60. Color threshold was adjusted
to white or green to outline birefringent or fluorescent crystals respectively. The analyze
> ‘analyze particle’ function was used to quantify the crystals using a pixel size of 0infinity, circularity of 0.00-1.00 and the outlines option checked. This analysis provided
us with the total particle count, average particle size and the area occupied by the
crystals. The data was statistically analyzed using Statistical Package for Social Sciences
(SPSS, Version 22.0.0.2 Mac, IBM Corp.).

2.4.6

In vivo Imaging of Drosophila Malpighian Tubules

Following the successful imaging of calcium oxalate stones in ex vivo Drosophila
malpighian tubes, we developed an innovative protocol for in vivo imaging. A transgenic
fly line expressing red fluorescent protein (RFP) was developed in order to visualize
malpighian tubules in vivo. Imaging this transgenic fly line allowed us to optimize our
imaging protocols for in vivo laser resonance confocal microscopy (Nikon Inc., Tokyo,
Japan).

2.4.6.1

Generation of RFP Expressing Drosophila Malpighian
Tubules

To create a transgenic fly line that expressed red fluorescent protein (RFP) in the
malpighian tubules, we used the established GAL4/UAS system for the genetic
manipulation of Drosophila melanogaster115. The GAL4/UAS system is a mating based
bi-partite system with spatio-temporal control. Two fly lines were obtained, one
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expressing the yeast transcription activation factor (GAL4) in its malpighian tubules and
a second, which had an upstream activation sequence (UAS), followed by sequence
coding for the RFP protein. The progeny of this cross expressed both GAL4 which bound
the UAS sequence and drove gene expression, as illustrated in Figure 9. The driver
URO-GAL4 (Bloomington #44416) which expresses GAL4 in a urate oxidase pattern in
the principal cells of the malpighian tubules, was crossed with the responder line UASRFP (Bloomington #32218) to produce a transgenic RFP expressing fly. This transgenic
line was reared at 29°C for optimal activation of the UAS/GAL4 system.

Figure 9: Schematic diagram depicting the GAL4/UAS cross resulting in progeny that
expresses RFP in their malpighian tubules.
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2.4.6.2

Intravital Confocal Microscopy

Transgenic RFP expressing flies were anesthetized using CO2 narcotization. Imaging was
carried out using 4x and 10x objective lenses. The DAPI (408 nm) channel was utilized
to provide background contrast and the Alexa594 (594 nm) channel was used to outline
the red fluorescent malpighian tubules. Pinhole was set to 1.2 AU and laser energy set to
115 with a gain of 18. Multichannel and z-stack images were taken using the NISElements Advanced software (Nikon Inc., Tokyo, Japan) and analyzed with NISElements Analysis software (Nikon Inc., Tokyo, Japan).

2.5 Elemental Analysis of Isolated Drosophila Stones
To adequately compare the composition of human stones to Drosophila melanogaster
formed calcium oxalate stones, stone material formed by wild type Canton-S flies was
isolated and analyzed using scanning electron microscopy and energy-dispersive x-ray
spectroscopy to ascertain the elemental composition.

2.5.1

Drosophila Stone Isolation

150 wild type Canton-S flies were fed a 1% w/v sodium oxalate diet for 14 days. The flies
were then transferred to an empty vial and euthanized with CO2 narcotization (Flystuff
Inc., San Diego, United States) for 10 minutes. These flies were dissected under a
dissecting microscope (AmScope Inc., Irvine, United States) in Schneider’s Media (0146
Sigma Aldrich Inc.) and the malpighian tubules removed. The dissected tubules were
transferred to a 1 ml Eppendorf tube containing 1 ml of distilled water. The sample was
centrifuged (Eppendorf Inc., Hamburg, Germany) at 15000 rpm for 5 minutes forming a
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pellet of stone material and malpighian tubule tissue. The supernatant was carefully
pipetted out without disturbing the pellet. 0.5 ml of Proteinase K (5568 Sigma Inc.) at a
concentration of > 500 units/ml and 200 µl of 0.1% Triton-X (BDH Chemicals Inc.) was
added. Proteinase K performs optimally in the presence of a detergent. The pellet was
then broken up using a pipette and placed in a water bath at 37°C for 12-24 hours. After
this time, the Eppendorf tube was removed from the bath, inspected for dissolution of the
tissue and then centrifuged (Eppendorf Inc., Hamburg, Germany) at 15000 rpm for 5
minutes. The supernatant removed and the wash repeated 2-3 times to remove any
remaining organic material and impurities. The sample was then suspended in 500 µl of
distilled water for use in scanning electron microscopy and energy dispersive x-ray
spectroscopy analysis. At this point the sample could also be stored in a −80°C freezer for
analysis at a later date.

2.5.2

Scanning Electron Microscopy and Energy Dispersive X-ray
Spectroscopy (SEM/EDX)

Scanning electron microscopy and energy dispersive x-ray spectroscopy analysis was
performed at Surface Sciences Western University, London, Ontario. 20 µl of isolated
stone sample suspended in distilled water was added to the surface of a 5 mm x 5 mm
silica wafer (Ted Pella Inc., Redding, United States) and air dried at 60°C for 2 hours.
The wafer and sample were then sputtered with a thin layer of gold to increase
conductivity for imaging. Scanning electron microscopy images were obtained with a
Hitachi S4500 Field emission SEM (Hitachi Inc., Tokyo, Japan) using a 15.0 kV electron
beam voltage. Energy dispersive x-ray spectroscopy analysis of the elemental
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composition was done using a Quartz X One EDX System (Quartz Imaging Corporation,
Vancouver, Canada). EDX graphs for elemental composition and atomic weight
distribution of elements were obtained.

2.6 High-Throughput Drug Screening Platform
An experimental drug library containing 360 compounds was obtained through
collaboration with Dr. Paul Spagnuolo at the School of Pharmacy, University of
Waterloo, Waterloo, Canada. The experimental drug library is based on plant extracts
with known regulatory activity in the human diet and has successfully been used as a
starting point for rational drug design in previous studies130,133. The drug compounds
were dissolved in DMSO and distributed into eight 96 well plates, in cohorts of 24 drugs
per plate and stored in a −80 °C freezer until further use. A master list of the drugs and
their concentrations were maintained in a Microsoft excel file for further reference. Drug
screening was performed with an indirect approach to quantifying stone burden following
treatment.

2.6.1

Assessment of DMSO on Drosophila Survival

Since our drug library used DMSO as a solvent, before the addition of drug compounds
to the Drosophila diet, the effect of DMSO on the Drosophila survival was investigated.
Four concentrations of DMSO 0.1%, 0.3%, 0.5% and 1% w/v, were evaluated to assess
effects of DMSO on Drosophila survival using a similar protocol to the one described
above.
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2.6.2

Development of High-throughput Drug Screening Platform

Drosophila melanogaster have two pairs of malpighian tubules that coalesce into a
common ureter and drain urine plus other materials into the gut at the junction between
the mid and the hindgut. We observed that insects that form stones also excrete stone
material into the fecal matter, providing an indirect means for assessing stone burden.
Apart from feeding, most flies rest, mate and excrete on vertical surfaces such as the
inside of the polypropylene fly vial.
A 0.5% w/v sodium oxalate diet was prepared based on our prior survival and stone
burden data for the various lithogenic agents. This agent and concentration were chosen
for drug screening due to the optimal balance between fly survival and stone burden. 200
µl of drug-DMSO solution was added to 5 ml of sodium oxalate food media during the
preparation of the media to a final concentration of 10 µM. The drug was thoroughly
mixed to ensure adequate distribution. Cohorts of 48 drugs were prepared for screening
on a weekly basis. A 22 mm x 22 mm glass coverslip (C9802 Sigma Inc.) was inserted
vertically into the cellulose acetate plug, where it served as a surface for flies to rest and
excrete fecal matter. 30 Wild type Canton-S flies were added to the drug vials and
allowed to feed for 7 days. Wild Type Canton-S flies in 0.5% sodium oxalate media
without drug and standard media were used as controls. After 7 days, the flies were
discarded and the glass coverslips with deposited fecal matter were subjected to polarized
light and confocal microscopy (Nikon Inc., Tokyo, Japan). All images were analyzed
using Image J software (NIH http://imagej.nih.gov) with a potential drug ‘hit’ considered
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if birefringent stone material in the fecal matter was reduced by > 50 % as compared to
controls (Figure 10).

Figure 10: Diagram illustrating the drug screening vial setup, plus bright field and
polarized microscopy of coverslips with Drosophila fecal matter laden with calcium
oxalate stone material in the 0.5% w/v sodium oxalate group.
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Chapter 3

3

Results

3.1 Drosophila Lifespan Studies
3.1.1

Survival in Sodium Oxalate Diet

Under standard laboratory conditions, the mean survival time for control wild type
Canton-S fed standard food media was 32.09 days (Table 3). Sodium oxalate at a
concentration of 0.05% w/v did not adversely affect survival.

Means and Medians for Survival Time
Diet Type

Mean
Std.

a

Median
95% CI

Est.

a

95% CI

Std.
Est.

Err

Low.

Upp.

Err

Low.

Upp.

Standard

32.09

.75

30.60

33.58

32.0

.96

30.10

33.89

NaOx 0.05%

31.59

1.13

29.37

33.80

33.0

1.63

29.80

36.19

NaOx 0.1%

27.32

.63

26.08

28.55

28.0

.33

27.33

28.66

NaOx 0.5%

21.58

.59

20.41

22.76

23.0

.44

22.12

23.87

NaOx 1%

15.11

.46

14.21

16.01

15.0

.44

14.12

15.87

Overall

23.70

.49

22.73

24.67

24.0

.58

22.85

22.14

Table 3: Means and medians for survival of wild type Canton-S in varying concentrations
of sodium oxalate media. Estimation is limited to the largest survival time if it is censored.
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Increasing the concentration of sodium oxalate to 0.1% and 0.5% w/v resulted in a 14.8%
and 32.7% reduction in survival respectively. A 1% w/v concentration of sodium oxalate
caused a 52.9% reduction in survival as compared to controls, with a mean life span of
15.12 days. A Kaplan Meier survival analysis of wild type Canton-S fed varying
concentrations of sodium oxalate is illustrated in Figure 11.

Figure 11: Kaplan Meier survival analysis of wild type Canton-S fed various concentrations
of the lithogenic agent sodium oxalate for a period of 40 days.

Both male and females survived for an average of 32 days on standard food media.
Interestingly, females on a 0.05% w/v sodium oxalate diet survived for longer (34.07
days) as compared to males fed a similar diet or standard diet. Male flies fed a 0.1% w/v
sodium oxalate diet survived for an average of 1.64 days longer than females fed a
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similar diet. No statistically significant differences in survival between sexes was
observed for 0.5% and 1% w/v sodium oxalate diet. A Kaplan Meier analysis comparing
survival between male and female wild type Canton-S is illustrated in Figure 12.

Figure 12: Kaplan Meier survival analysis of male and female wild type Canton-S fed
various concentrations of the lithogenic agent sodium oxalate for a period of 40 days.

A log-rank test revealed a statistically significant (p value < .0001) difference in survival
between wild type Canton S fed increasing concentrations of the lithogenic agent sodium
oxalate (Table 4).
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Chi-square

df

Sig.

327.547

4

< .0001

257.578

4

< .0001

290.168

4

< .0001

Log-Rank
(Mantel Cox)
Breslow
(Generalized
Wilcoxon)
Tarone-Ware

Table 4: Statistical analysis of the survival distributions for the different Drosophila diet
types.

3.2 Development of Novel Imaging Modalities in Drosophila
To develop imaging modalities in the Drosophila melanogaster model of human calcium
oxalate nephrolithiasis, the novel bisphosphonate based fluorescent probes AlendronateFITC and its negative control Notdronate-FITC were developed for ex vivo imaging.

3.2.1

Specificity of Bisphosphonate Based Fluorescent Probes

To assess the specificity of our bisphosphonate based fluorescent probes to
hydroxyapatite and calcium containing stones, we subjected synthetic hydroxyapatite
particles (Figure 13) and pulverized samples of infrared spectroscopy confirmed human
calcium oxalate stones (Figure 14) to bright field, polarized light and fluorescent
microscopy.
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Figure 13: Synthetic hydroxyapatite subjected to brightfield, polarized light and
fluorescent microscopy after straining with alendronate-FITC and notdronate-FITC. Scale
bars = 100 µm

Both synthetic hydroxyapatite and pulverized human calcium oxalate stones showed
brilliant birefringence under polarized light (Figure 13 B, Figure 14 B). Synthetic
hydroxyapatite particles stained with Alendronate-FITC exhibited high fluorescent signal
intensity (Figure 13 C) when subject to a 488 nm wavelength blue FITC laser, as
compared to those stained with Notdronate-FITC (Figure 12 D).

Figure 14: Pulverized calcium oxalate human stone sample subjected to brightfield,
polarized light and fluorescent microscopy after straining with alendronate-FITC and
notdronate-FITC. Scale bars = 100 µm
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Similar results were obtained with the pulverized human calcium oxalate stone sample
(Figure 14 C, Figure 14 D), suggesting that Alendronate-FITC selectively binds to
hydroxyapatite and calcium containing stones.

3.2.2

Ex vivo Imaging of Drosophila Malpighian Tubules

Wild type Canton-S were used for this experiment. 20-30 flies were added to lithogenic
diets containing sodium oxalate or ethylene glycol at concentrations of 0.05%, 0.1%,
0.5% and 1% w/v for a period of 14 days. The malpighian tubules were subsequently
dissected and stained with Alendronate-FITC or Notdronate-FITC. Images were taken
with polarized light and fluorescent microscopy (Figure 15, Figure 16).

3.2.2.1

Sodium Oxalate Diet

Wild type Canton-S fed a sodium oxalate diet, under polarized light exhibited brilliant
birefringence throughout the anterior and posterior malpighian tubules with finer crystals
scattered throughout (Figure 15 A, B, C, D). At lower concentrations of 0.05% and 0.1%
w/v sodium oxalate the calculi are deposited in the initial segments of the malpighian
tubules (Figure 15 A, B). At higher concentrations of 0.5% and 1% w/v sodium oxalate
fine calculi can be seen occupying the whole malpighian tubule, specifically concentrated
in the main segments of the tubule (Figure 15 C, D).
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Figure 15: Polarized light and fluorescent microscopic analysis of malpighian tubules
following feeding with various concentrations of sodium oxalate. Scale bars = 100 µm

Malpighian tubules from wild type Canton-S stained with Alendronate-FITC exhibit a
fluorescent signal that closely corresponds to the areas of birefringence shown by
polarized light microscopy (Figure 15 E, F, G, H). Fluorescent signal intensity is
concentrated in the initial parts of the malpighian tubule for 0.05% and 0.1% w/v sodium
oxalate (Figure 15 E, F). At higher concentrations of 0.5% and 1% w/v sodium oxalate
fluorescent signal is observed throughout the tubule lumen (Figure 15 G, H). Signal
intensity increased with increase in sodium oxalate dosage. Tubules stained with
Notdronate-FITC did not reveal any fluorescent signal (Figure 15 I, J, K, L).

3.2.2.2

Ethylene Glycol Diet

Wild type Canton-S fed an ethylene glycol diet exhibited a more scattered pattern of
birefringence in the malpighian tubules, as compared to the sodium oxalate diet. At lower
concentrations of 0.05% and 0.1% w/v ethylene glycol calculi can be seen scantily
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dispersed throughout the malpighian tubule and not restricted to the initial segments
(Figure 16 A, B). At higher concentrations of 0.5% and 1% w/v ethylene glycol the
distribution of calculi is denser, with more calculi concentrated in the main segment of
the tubule (Figure 16 C, D).

A
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D

E

F

G

H

I

J

K

L

Figure 16: Polarized light and fluorescent microscopic analysis of malpighian tubules
following feeding with various concentrations of ethylene glycol. Scale bars = 100 µm

Flies fed a 0.05% and 0.1% w/v ethylene glycol and stained with Alendronate-FITC,
exhibited similar scanty fluorescent signal intensity throughout the malpighian tubule
(Figure 16 E, F). At higher concentrations of 0.5% and 1% w/v ethylene glycol there is a
strong fluorescent signal throughout the tubule, especially the main segments (Figure 16
G, H). Notdronate-FITC again does not exhibit fluorescent signal at any concentration of
lithogenic diet (Figure 16 I, J, K, L).
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3.2.2.3

Statistical Analysis

Wild type Canton S fed a sodium oxalate diet formed calcium oxalate calculi that were
on average 4.96 µm in size. Flies fed an ethylene glycol diet produced calculi that were
approximately 59.5% (12.25 µm) larger than those fed the sodium oxalate diet, however,
these calculi were distributed haphazardly throughout the tubule.

Figure 17: Polarized light microscopy group: Comparison between tubule stone count,
average stone size & total area of tubule occupied in flies fed varying concentrations of
sodium oxalate & ethylene glycol.

Flies fed either the sodium oxalate diet or ethylene glycol diet showed an increase in
stone burden in response to increase in lithogenic agent concentration (Figure 17).
However, the sodium oxalate diet group showed a more linear response and stone
distribution throughout the malpighian tubule. Increasing the concentration of sodium
oxalate to 0.5% and 1% w/v resulted in a 6-fold and 43-fold increase in stone count as
compared to 0.05% w/v. Ethylene glycol showed more modest results, with a 2-fold and
9-fold increase in stone count at concentrations of 0.5% and 1% w/v respectively.
Fluorescent signal intensity data for both groups is illustrated in Figure 18.
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Figure 18: Fluorescent microscopy group: Comparison between tubule stone count,
average stone size & total area of tubule occupied in flies fed varying concentrations of
sodium oxalate & ethylene glycol.

3.2.3

In vivo Imaging of Drosophila Malpighian Tubules

Transgenic flies and larvae expressing RFP in the malpighian tubules were imaged using
dual laser fluorescence confocal microscopy.

3.2.3.1

Intravital Confocal Microscopy

Immobilized transgenic RFP expressing larvae showed bright red malpighian tubules that
were clearly visible through the larval fat body (Figure 19 A). No malpighian tubules
were visible in control wild type Canton-S larvae. Fine peristaltic movements of the
tubules in the hemolymph were visible. The DAPI channel provided adequate contrast to
the red fluorescent malpighian tubules allowing them to be visualized in their entirety
(Figure 19 A, Figure 19 B). Minimal amount of red auto-fluorescence was present in the
Alexa 594 channel (Figure 19 C).
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Figure 19: (A) Intravital imaging of live Drosophila larvae expressing RFP in the malpighian
tubules using dual channel (B) DAPI & (C) Alexa 594 laser confocal microscopy.

Bright red anterior and posterior malpighian tubules were clearly visualized in the
thoraco-abdomen of adult transgenic RFP expressing Drosophila group (Figure 20). No
malpighian tubules were visible in the wild type Canton-S control group. Imaging was
easier with the insect in supine position as compared to other orientations. The DAPI
channel provided good contrast to the exoskeleton and external fly structures, allowing
for the visualization of RFP tubules (Figure 20 A, Figure 20 B). Minimal autofluorescence, except for the eyes, was seem in the adult fly (Figure 20 C).

Figure 20: (A) Intravital imaging of live adult Drosophila expressing RFP in the malpighian
tubules using dual channel (B) DAPI & (C) Alexa 594 laser resonance confocal
microscopy.
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3.3 Elemental Analysis of Drosophila Stones
3.3.1

Scanning Electron Microscopy & Energy Dispersive X-ray
Spectroscopy

SEM images revealed calcium oxalate calculi with sizes ranging between 6 to 16 µm,
often exhibiting spectacular shapes and configurations (Figure 21 A, Figure 22 A). Two
composition types, calcium oxalate monohydrate (Figure 21, Figure 23) and calcium
oxalate dihydrate (Figure 22) were predominately present in the sample. Calcium oxalate
monohydrate crystals, also known whewellite, exhibit the classic dumbbell shaped
crystals (Figure 21 A) similar to crystals observed in human urine samples. While
calcium oxalate dihydrate or weddellite, exhibited the classic envelope shaped crystals
(Figure 22 A).

Figure 21: (A) Scanning electron micrograph of Drosophila calcium oxalate monohydrate
stone. (B) Graphical representation of EDX analysis showing elemental distribution in
Drosophila calcium oxalate monohydrate stone.
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Energy dispersive x-ray spectroscopy analysis of the isolated stones revealed peaks of
calcium (Figure 21 B, Figure 22 B, Figure 23 B) plus peaks of carbon and oxygen in
ratios of 1:1 (Figure 21 B) and 1:2 (Figure 22 B). The peaks of gold and silicon relate to
the underlying silica wafer on which the sample was mounted and surface sputtering of
gold during preparation of the sample.

Figure 22: (A) Scanning electron micrograph of Drosophila calcium oxalate dihydrate
stone. (B) Graphical representation of EDX analysis showing elemental distribution in
Drosophila calcium oxalate dihydrate stone.

Occasionally, some calculi showed the presence of small amounts of magnesium (Figure
22 B, Table 5), similar to human calcium oxalate stones134.
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Figure 23: (A) Scanning electron micrograph of Drosophila calcium oxalate monohydrate
stone. (B) Graphical representation of EDX analysis showing elemental distribution in
Drosophila calcium oxalate monohydrate stone.

The atomic weight distributions of elements present in stones isolated from Drosophila
Melanogaster tubules are listed in Table 5. Carbon and oxygen are the predominant
elements and occur in a similar distribution as compared to human stone samples
analyzed by energy dispersive x-ray spectroscopy134.
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Atomic Weight
Calcium

Carbon

Oxygen

Magnesium

8.72

43.11

48.17

0.00

10.71

27.64

61.35

0.30

8.18

34.81

57.01

0.00

18.17

31.71

24.33

1.67

Percentages
Calcium Oxalate
Monohydrate
Calcium Oxalate
Dihydrate
Calcium Oxalate
Monohydrate
Human Stone
Sample

134

Table 5: Energy dispersive x-ray spectroscopy analysis of Drosophila stones
demonstrating the elemental distribution in atomic percentages.

A comparison between the relative size of calcium oxalate stones (Figure 24 B, solid
arrow) to the malpighian tubule lumen (Figure 24 B, dashed arrow) is illustrated in the
SEM image below. Large stones obstructing the common ureter were occasionally seen
in flies fed lithogenic diets (Figure 24 A).
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Figure 24: (A) Light microscope image demonstrating the four malpighian tubules (arrows)
with a large central stone lodged in the ureter. (B) Scanning electron micrograph of a
Drosophila malpighian tubule (dashed arrow) and Drosophila stones (solid arrow).

3.4 High-throughput Drug Screening Platform
Due to the anatomical relationship of Drosophila malpighian tubules to the gut, flies
drain urine and other materials into the fecal matter. We have developed a non-invasive
high-throughput screening method to measure stone burden in the fecal matter using
polarized and confocal microscopy. We use this novel screening method to screen
through a library of 360 experimental drugs to identify compounds that reduce calcium
oxalate stone formation.

3.4.1

Assessment of DMSO on Drosophila Survival

The average life span of flies fed a 0.1% and 0.3% w/v DMSO diet was 38 and 36 days
respectively. This was similar to the life span of 40 days in control wild type Canton-S
fed a standard diet. Life span at concentrations of 0.5% and 1% w/v DMSO was reduced
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to 25 days and 15 days respectively. At concentrations higher than 0.3% w/v of DMSO,
time to eclosion was prolonged, with an overall reduction in fly life span. These results
are in line with previous literature135.

3.4.2

Development of High-throughput Drug Screening Platform

Dual channel confocal microscopy with polarized transmitted light was used for analysis
of Drosophila fecal matter deposited onto glass coverslips. EGFP and Alexa594 were
used for background fluorescence to provide contrast for calcium oxalate stone material.
Two control groups, one fed a standard diet and another a 0.5% w/v sodium oxalate diet
were analyzed at the start of the experiment to produce baseline controls. Wild type
Canton-S flies fed a standard diet did not show the presence of any calcium oxalate stone
material in the fecal matter as shown in Figure 25.

Figure 25: (A,B,C) Confocal and (D) polarized light analysis of fecal matter from flies fed a
standard diet. (A) Merged image of GFP, Alexa594 and polarized light channels show no
presence of calcium oxalate stone material.
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Wild type Canton-S control group fed a 0.5% w/v sodium oxalate diet showed numerous
calcium oxalate crystals in the fecal matter as shown in Figure 26. Stone size and
morphology were similar to those isolated directly from the malpighian tubules in our
scanning electron microscopy and energy dispersive x-ray spectroscopy analysis. This
suggests that intact stone material is excreted into the fecal matter via the malpighian
tubules. The EGFP and Alexa594 provided adequate background contrast to the fecal
matter allowing for the visualization and quantification of stone material.

Figure 26: (A,B,C) Confocal and (D) polarized light analysis of fecal matter from flies fed a
0.5% w/v sodium oxalate diet. (A) Merged image of GFP, Alexa594 and polarized light
channels show abundant calcium oxalate crystals in the fecal matter.
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Figure 27: Polarized light microscopy images of fecal matter from stone forming
Drosophila fed a panel of 24 drugs. Potential 'hits' are outlined in red.

Following the establishment of our control groups, cohorts of 24 drugs were tested per
week and analyzed using polarized light microscopy (Figure 27). A drug was considered
a ‘hit’ if stone formation was reduced by > 50% compared to our control groups. Drugs
that caused toxicity or reduction in life span were re-evaluated at a lower concentration.
Drugs that were considered potential ‘hits’ were re-evaluated through direct visualization
and quantification of stone burden in malpighian tubules following dissection.
A total of 6 drugs compounds that reduced calcium oxalate stone formation were
identified and are outlined in Table 6.
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Drug ‘Hits’
1

Aloin B

2

Alpha-mangostin

3

Apiin

4

Arbutin

5

Cucurbatacin B

6

Isorhamnetin

Table 6: List of drugs that reduce calcium oxalate stone formation in the Drosophila model
of human nephrolithiasis.
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Chapter 4

4

Discussion and Conclusions

In this project we demonstrate the versatility and advantages of Drosophila melanogaster
as a novel model for human nephrolithiasis. We highlight the ease with which calcium
oxalate stones are formed, in a highly reliable fashion, through simple dietary
manipulation. Furthermore, we demonstrate new imaging modalities for measuring stone
burden both in vivo and ex vivo. We have identified 6 compounds, from a large scale
screen of 360 experimental drug compounds, that inhibit calcium oxalate stone
formation.

4.1 Drosophila Life Span Studies
An ideal model for kidney stone disease should be simple, amenable to imaging and have
an adequate life span to provide sufficient time to study stone formation or test the effect
of a therapeutic agent. Lithogenic agents such as sodium oxalate and ethylene glycol act
by producing a state of hyperoxaluria. Sodium oxalate is a potent source of oxalate and
ethylene glycol serves as a precursor for oxalate formation. However, these lithogenic
agents can also be toxic. For our model to be useful we decided to carry out life span
studies in order to identify the optimal concentrations of lithogenic agents for use in
subsequent experiments. Sodium oxalate was chosen as a lithogenic agent of choice due
to our ex vivo imaging results which showed that sodium oxalate produced calcium
oxalate stones in a more linear fashion compared to ethylene glycol.
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A mean survival time of 32.09 days in the control wild type Canton-S group was in line
with lifespans reported in other studies. Sodium oxalate at concentrations of 0.05% w/v
did not adversely affect survival. Surprisingly, female flies fed sodium oxalate at this
concentration survived for longer than the control group. A larger sample size is needed
to validate this trend. At 0.05% w/v sodium oxalate, the flies produced minimal calcium
oxalate stones and hence this concentration was not used for any of our subsequent
experiments. At 0.1% w/v and 0.5% w/v sodium oxalate the flies survived for 27.32 and
21.58 respectively. At these concentrations wild type Canton-S flies produced stones
throughout the main segment of the malpighian tubules. Both these concentrations are
considered suitable for ex vivo and in vivo imaging as they produced an adequate stone
burden. A 0.5% w/v concentration of sodium oxalate was used for our high throughput
drug screening platform. The average life span of 21 days provided an adequate time
frame for assessing the effects of the experimental drugs on stone burden. At 1% w/v
sodium oxalate fly survival was severely affected with an average survival time of 15.11
days. This concentration of sodium oxalate was used in the SEM/EDX analysis
experiment as the flies produced the maximum amount of stones allowing for better stone
isolation and sample yield. This concentration is not recommended for drug screening or
imaging purposes. There was no difference in survival or stone burden between sexes,
hence sex segregation was not required for any of our subsequent experiments.

4.2 Development of Novel Imaging Modalities in Drosophila
One of the main drawbacks of current animal models of nephrolithiasis is difficulty in
monitoring stone burden. We describe the superiority of the Drosophila model which is
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amenable to both ex vivo and in vivo visualization and quantification of stone burden. We
repurposed the bisphosphonate Alendronate and conjugated it to the fluorophore
fluorescein isothiocyanate. We also developed a negative control Notdronate, that is
similar to Alendronate but lacks the functional bisphosphonate ring. Bisphosphonates
bind strongly to calcium and hydroxyapatite allowing for visualization and quantification
of stone burden in the malpighian tubules.

4.2.1

Bisphosphonate Based Fluorescent Probes

To assess the specificity of our bisphosphonate based fluorescent probes to
hydroxyapatite and calcium containing stones, we subjected synthetic hydroxyapatite
particles and pulverized samples of infrared spectroscopy confirmed human calcium
oxalate stones to bright field, polarized light and fluorescent microscopy.
Alendronate-FITC strongly bound to synthetic hydroxy apatite particles and human
calcium oxalate stone material, while our negative control did not show any binding. This
study validates the use of Alendronate-FITC for ex vivo and in vivo imaging.

4.2.2

Ex vivo Imaging of Drosophila Malpighian Tubules

This study aimed to visualize and quantify calcium oxalate stone burden using the two
lithogenic agent’s sodium oxalate and ethylene glycol at concentrations of 0.05%, 0.1%,
0.5% and 1% w/v. Our results show that sodium oxalate is the more reliable lithogenic
agent as compared to ethylene glycol which produces scanty and haphazard stones
throughout the malpighian tubules. Sodium oxalate at concentrations of 0.1% and 0.5%
w/v produced stones in the main segments of the malpighian tubules. These
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concentrations were used for our subsequent drug screening experiments. A
concentration of 1% w/v sodium oxalate produced the highest number of stones and was
used for our scanning electron microscopy and energy dispersive x-ray spectroscopy
analysis.

4.2.3

In vivo Imaging of Drosophila Malpighian Tubules

To our knowledge this is the first report of intravital confocal imaging of Drosophila
malpighian tubules. This section of our study develops a unique protocol for imaging
Drosophila malpighian tubules in vivo using a transgenic red fluorescent protein
expressing fly. We were successful in imaging malpighian tubules in both live larvae and
adult flies. This platform will serve as a starting point for intravital imaging in the
Drosophila model of nephrolithiasis and provide real-time information on the sites where
crystallization begins plus help in monitoring stone burden to the assess the effects of
therapeutic interventions.

4.3 Elemental Analysis of Drosophila Stones
We extracted and isolated stones formed by Drosophila for use in scanning electron
microscopy and energy dispersive x-ray spectroscopy analysis to ascertain their elemental
composition. For our model to be truly translatable to human nephrolithiasis, the stones
formed should be similar in composition to their human counterparts.
The protocol that we developed for stone extraction and isolation was successful and
provided an adequate sample yield. Proteinase K based malpighian tubule dissolution did
not adversely affect the formed calcium oxalate stones. It was noted that a minimum of
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150 dissected flies were required for sufficient sample collection. In some cases, light
sonication for 30 minutes helped dislodge the stones from the malpighian tubules.
SEM analysis revealed that in the presence of the lithogenic agent’s sodium oxalate and
ethylene glycol, Drosophila formed predominately calcium oxalate stones. Both of the
monohydrate and dihydrate forms of calcium oxalate were observed. Scanning electron
microscopy analysis demonstrated pathognomonic dumbbell shaped calcium oxalate
monohydrate crystals and envelope shaped calcium oxalate dihydrate crystals. Crystal
size ranged between 6 to 16 µm which is roughly equal to the size of the malpighian
tubule lumen and similar to the size of crystals formed in rat models of nephrolithiasis98.
Energy dispersive x-ray spectroscopy analysis showed peaks of calcium (9.2% ± 1.33),
carbon (35.1% ± 7.74) and oxygen (55.5% ± 6.71) which confirms that the crystal
composition is predominantly calcium oxalate (Ca(COO)2). Carbon and oxygen was
found in ratios of 1:1 and 1:2 which corroborates the di-anionic structure of oxalate.
Trace amounts of magnesium were also observed in the calcium oxalate stones which is
similar to that found in human stones. Our SEM/EDX analysis proves that the calcium
oxalate stones formed in Drosophila closely resemble human calcium oxalate
nephrolithiasis134.

4.4 High-throughput Drug Screening Platform
As highlighted in the introduction to this project, kidney stone disease continues to be a
significant healthcare issue and accounts for a large portion of urological practice. The
advent of minimally invasive surgical techniques such as ureteroscopy (URS),
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extracorporeal shockwave lithotripsy (ESWL), and percutaneous nephrolithotomy
(PCNL) have led to improved clinical outcomes in patients with kidney stone disease,
however, advancements in the medical management of kidney stones are severely
lacking. Current medical therapies focus on prevention of kidney stones through dietary
modification, such as increased fluid intake whilst limiting the intake of animal protein,
dietary oxalate and sodium. Few, if any, drugs exist that directly target stone formation.
Current therapies involve the use of thiazide diuretics such as hydrochlorothiazide and
chlorthalidone, that act by inducing minor volume depletion leading to the reabsorption
of sodium and concomitant passive reabsorption of filtered calcium136,137. A reduction in
urinary calcium leads to a decreased risk of calcium oxalate stone formation. However,
the use of thiazide diuretics is a preventative measure and does not affect stones that have
already formed. Potassium citrate, a potent citrate source, is commonly prescribed as
citrate forms complexes with enteric calcium and prevents it from binding to oxalate138.
Potassium citrate can also quickly metabolize to bicarbonate and is used to alkalinize the
urine in patients with uric acid stone disease. Xanthine oxidase inhibitors such as
Allopurinol are used to reduce uric acid production and are useful in both patients with
uric acid and calcium oxalate stone disease139–141. A need exists for improved medical
management of kidney stone disease.
This section of our study utilizes the novel Drosophila melanogaster model of human
calcium oxalate nephrolithiasis to screen through a library of 360 nutraceutical
compounds to identify drugs that inhibit stone formation. The rationale for using this
drug library stems from the proven association between the diet and kidney stone disease.
Furthermore, nutraceuticals have been an effective starting point for rational drug design
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in the past130. For example, Faber et. al. in their landmark paper discovered that
administration of folic acid in children with acute lymphoblastic leukemia (ALL) caused
an exacerbation of the disease process which ultimately led to the development of the
now commonly used anti-metabolite chemotherapeutic agents142. Similar drug libraries
have recently been used to identify novel chemotherapeutic drugs133.
As with prior animal models, no method existed for large scale drug screening in the
Drosophila model of human kidney stone disease. Our novel indirect screening method
for measuring stone burden in fly fecal matter was highly effective. Large cohorts of
drugs were easily screened in weeks using simple polarized and confocal microscopy.
The experimental protocol proved simple, was easily learned and did not require an
extensive infrastructure.
A total of 6 compounds that reduced calcium oxalate stone formation were identified for
a total of 360 compounds. A brief literature search revealed interesting information
regarding the possible mechanisms by which these drugs may have exerted their effect.
Aloin B is an anthrone derived from the leaves of the plant Aloe trichosantha. It is a
potent chloride channel activator that initiates peristalsis in human tissues such as the gut
and kidneys. Peristaltic action could potentially lead to early clearance of smaller calcium
oxalate crystals limiting their ability to form larger stones. Aloin B is a known
antimicrobial with a broad spectrum of action143. Since kidney stones are associated with
urinary tract infections, the action of Aloin B on the renal microbiome could reduce the
risk of stone formation. Additionally, Aloin B is also an antioxidant with antiinflammatory properties, as shown in prior studies144. Neutralization of reactive oxygen
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species in the urinary tract and reduction of the inflammation associated with the
deposition of calcium oxalate crystals could also reduce the risk of stone formation.
Alpha Mangostin is a xanthoid that is isolated from the mangosteen tree. Previous studies
on its pharmacological activity have shown potent anti-oxidant, anti-microbial and antiinflammatory properties145,146. Similarly, mangostin is basic in nature and could
potentially alkalinize the urine leading to effects similar to that of potassium citrate.
Cucurbatacin B is compound that imparts a bitter taste to plant species in the
Cucurbitaceae family which includes squashes and pumpkins. It has known anti-cancer
properties as shown in a number of studies147,148.
Arbutin is a glycoside that inhibits tyrosinase and is extracted from the leaf of the
bearberry plant. It has previously been used in traditional Cherokee medicine as a urinary
tract infection remedy and recent studies have validated its antimicrobial effect149.
Isorhamnetin is a methylated flavonoid that is isolated from the psychedelic plant Tagetes
lucida. Isorhamnetin has known anti-mycobacterial and anti-inflammatory properties plus
stabilizing effects on the renal cell membrane150–152. There is some evidence of the
potential action of Isorhamnetin on Vitamin D receptor (VDR) activation that might
cause changes in calcium metabolism leading to a decreased risk of calcium oxalate
stone formation153.
Apiin is an aglycone isolated from parsley and celery. It and other apigenins have been
previously used for treatment of urinary tract infections and urolithiasis154. It acts by
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exerting a diuretic action through the inhibition of the Na+K+ATPase pump in renal
tissues155.
Our drug screening platform has yielded some interesting results. Further investigation of
the possible mechanisms of action of these drugs will be required to validate these
results.

4.5 Future Directions
Future work in this area will aim to elucidate the mechanisms of action of these drugs.
We also wish to screen larger libraries of FDA approved drugs to further strengthen our
results. Additionally, we have developed and optimized protocols for in vivo imaging of
Drosophila nephrolithiasis. Our next step will be to use our novel bisphosphonate based
fluorescent probes to visualize stone formation in real time. This will provide us with
vital information on where and how crystallization begins, possibly exposing new
therapeutic targets.
Most nephrolithiasis research is targeted towards the prevention and treatment of calcium
oxalate stones which is the most common subtype. We also aim to develop additional
Drosophila models for other stone types such as cystine and uric acid. Work is currently
underway to develop a simple genetic Drosophila model for cystine nephrolithiasis. We
have identified 16 DM orthologues for the human cystine co-transporters SLC3A1 and
SLC7A9 using the Drosophila RNAi Orthologue Online Prediction Tool (Figure 28). Of
the 16 gene orthologs identified, fly gene CG9413 is an exact match for structure and
function in the fly renal tubules. Using this data, we have created a transgenic fly that
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possesses the SLC7A9 gene knockdown in the principal cells of the malpighian tubules
by utilizing GAL4/UAS system. Two fly lines were obtained, one expressing the yeast
transcription activation factor (GAL4) in its renal tubules and a second fly line in which
an upstream activation sequence (UAS) is followed by a hairpin dsRNA sequence
directed against gene CG9413. The mating of these lines resulted in a selective
knockdown of the cystine co-transporter in the principal cells of the malpighian tubule.

Figure 28: Results of the DIOPT-DIST database search for Drosophila orthologs of human
SLC7A9 and SLC3A9 genes.

Initial results are promising. Highly birefringent crystals were observed the throughout
the malpighian tubule and gut in transgenic SLC7A9 knockdown Drosophila fed a 1%
cystine diet (Figure 29). Similar crystals were not seen in the control wild type Canton-S
group.
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Figure 29: Polarized light microscopy of malpighian tubules from transgenic SLC7A9
knockdown Drosophila fed a 1% cystine diet.

Scanning electron microscopy and energy dispersive x-ray spectroscopy analysis of
stones isolated from transgenic SLC7A9 knockdown Drosophila revealed large (> 100
µm) heterogeneous stones (Figure 30).
The stones were mostly composed of calcium and phosphate, however, there was a large
organic component. Further analysis of these stones with high performance liquid
chromatography – mass spectroscopy (HPLC-MS) is planned in the future.
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Figure 30: Scanning electron micrograph and energy dispersive x-ray diffraction
spectroscopy analysis of stones isolated from the transgenic SLC7A9 knockdown
Drosophila.

Similarly, we are also working on a Drosophila model for uric acid nephrolithiasis. Uric
acid, which is a byproduct of purine metabolism in humans, is converted to allantoin via
the action of the enzyme Uricase in invertebrates such as Drosophila. We have
developed a transgenic Uricase knockdown fly that produces uric acid concretions when
fed a diet high in purines (Figure 31).
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Figure 31: Polarized light microscopy of malpighian tubules from transgenic Uricase
knockdown Drosophila fed (A) standard food media (B) high yeast media (C) 1% purine
media.

SEM/EDX analysis of stones isolated from transgenic Uricase knockdown Drosophila
show a composition similar to that of human uric acid stones (Figure 32).

Figure 32: SEM/EDX analysis of stones isolated from transgenic Uricase knockdown
Drosophila. (A,B) Drosophila stone sample (C) Control human uric acid stone sample.
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Future experiments are planned to develop Drosophila models for other stone types such
as struvite, and screen large libraries of FDA approved drugs to identify potential
therapies. Work is also being done to investigate the effects of gut and urinary
microbiome on stone formation. We are confident that work in this novel model will
impact patient care and benefit patients with nephrolithiasis in a dramatic way.
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